LAG-3 and TIM-3 expression in melanoma and histopathological correlation: a single-center study.

IF 2.8 3区医学 Q2 ONCOLOGY

Clinical & Translational Oncology Pub Date : 2025-07-01 Epub Date: 2025-01-03 DOI:10.1007/s12094-024-03836-3

Mine İlayda Şengör Aygün, Özben Yalçın

{"title":"LAG-3 and TIM-3 expression in melanoma and histopathological correlation: a single-center study.","authors":"Mine İlayda Şengör Aygün, Özben Yalçın","doi":"10.1007/s12094-024-03836-3","DOIUrl":null,"url":null,"abstract":"Introduction: Melanomas originate from melanocytes and can be fatal. Surgical excision is primary, but due to potential rapid metastases, additional therapies are crucial. Our study aimed to assess Lymphocyte-activation gene 3 (LAG-3) and T-cell immunoglobulin and mucin domain 3 (TIM-3) expression in melanoma, exploring their relationships with survival and clinicopathological data.Methods: The study included 64 melanoma skin excision samples examined at the Pathology Department of Saglik Bilimleri University Prof. Dr. Cemil Tascioglu City Hospital between 2017-2023. LAG-3 and TIM-3 immunohistochemical studies were conducted by two pathologists to assess their expression rates and intensities. The study investigated correlations between these markers and epidemiological, clinical, and histopathological features of the cases. Statistical analysis was performed using SPSS 27, with significance levels set at p<0.05.Results: There was a significant association between LAG-3 and TIM-3 expressions (p: 0.001). LAG-3 expression correlated significantly with progression free survival (PFS) and overall survival (OS) rates (p: 0.020; p: 0.023). However, TIM-3 expression did not show significant correlations with PFS and OS times (p: 0.726; p: 0.903). Both LAG-3 and TIM-3 expressions were elevated in deceased patients (p: 0.001; p: 0.042). LAG-3 positivity was identified as an independent risk factor for OS, regardless of disease stage (p: 0.008).Conclusions: Research on immune checkpoint inhibitors has intensified in recent years. The expression of LAG-3 and TIM-3 is associated with poor prognosis in melanomas. Combined treatments targeting these markers may be beneficial in the treatment of this disease.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3084-3099"},"PeriodicalIF":2.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-024-03836-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Melanomas originate from melanocytes and can be fatal. Surgical excision is primary, but due to potential rapid metastases, additional therapies are crucial. Our study aimed to assess Lymphocyte-activation gene 3 (LAG-3) and T-cell immunoglobulin and mucin domain 3 (TIM-3) expression in melanoma, exploring their relationships with survival and clinicopathological data.

Methods: The study included 64 melanoma skin excision samples examined at the Pathology Department of Saglik Bilimleri University Prof. Dr. Cemil Tascioglu City Hospital between 2017-2023. LAG-3 and TIM-3 immunohistochemical studies were conducted by two pathologists to assess their expression rates and intensities. The study investigated correlations between these markers and epidemiological, clinical, and histopathological features of the cases. Statistical analysis was performed using SPSS 27, with significance levels set at p<0.05.

Results: There was a significant association between LAG-3 and TIM-3 expressions (p: 0.001). LAG-3 expression correlated significantly with progression free survival (PFS) and overall survival (OS) rates (p: 0.020; p: 0.023). However, TIM-3 expression did not show significant correlations with PFS and OS times (p: 0.726; p: 0.903). Both LAG-3 and TIM-3 expressions were elevated in deceased patients (p: 0.001; p: 0.042). LAG-3 positivity was identified as an independent risk factor for OS, regardless of disease stage (p: 0.008).

Conclusions: Research on immune checkpoint inhibitors has intensified in recent years. The expression of LAG-3 and TIM-3 is associated with poor prognosis in melanomas. Combined treatments targeting these markers may be beneficial in the treatment of this disease.

查看原文本刊更多论文

LAG-3和TIM-3在黑色素瘤中的表达及组织病理学相关性：一项单中心研究

黑色素瘤起源于黑色素细胞，可能是致命的。手术切除是主要的，但由于潜在的快速转移，额外的治疗是至关重要的。我们的研究旨在评估淋巴细胞活化基因3 （LAG-3）和t细胞免疫球蛋白和粘蛋白结构域3 （TIM-3）在黑色素瘤中的表达，探讨它们与生存和临床病理数据的关系。方法：该研究包括2017-2023年间在Saglik Bilimleri大学病理科教授Cemil Tascioglu市医院检查的64例黑色素瘤皮肤切除样本。2名病理学家进行LAG-3和TIM-3免疫组化研究，评估其表达率和强度。该研究调查了这些标志物与病例的流行病学、临床和组织病理学特征之间的相关性。采用SPSS 27进行统计学分析，显著性水平设为：结果：LAG-3与TIM-3表达有显著相关性（p: 0.001）。LAG-3表达与无进展生存期（PFS）和总生存期（OS）显著相关(p: 0.020；p: 0.023)。然而，TIM-3的表达与PFS和OS时间无显著相关性(p: 0.726；p: 0.903)。LAG-3和TIM-3的表达在死亡患者中均升高(p: 0.001；p: 0.042)。无论疾病分期如何，LAG-3阳性均被确定为OS的独立危险因素（p: 0.008）。结论：免疫检查点抑制剂的研究近年来不断加强。LAG-3和TIM-3的表达与黑素瘤的不良预后有关。针对这些标志物的联合治疗可能对治疗这种疾病有益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical & Translational Oncology 医学-肿瘤学

CiteScore

6.20

自引率

2.90%

发文量

240

审稿时长

1 months

期刊介绍： Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.